ViiV Healthcare announced the upcoming presentation of more than 60 abstracts showcased at two conferences this year: the 20th European AIDS Conference held in Paris, France, from October 15 – 18, and IDWeek 2025, held in Atlanta, Georgia, from…
Last fall, more than 100 people in 14 states got sick after eating at McDonald’s. The Centers for Disease Control and Prevention traced the outbreak to raw onions on the quarter-pounder hamburger, which were contaminated with Escherichia…
Michelle Weaver: Welcome to Thoughts on the Market. I’m Michelle Weaver, Morgan Stanley’s U.S. Thematic and Equity Strategist.
Today, a powerful force reshaping the financial lives of millions of Americans: inheritance.
It’s Friday, October 10th at 10am in New York.
Americans are living longer and they’re passing on their wealth later. Longevity is one of Morgan Stanley Research’s four key themes, and this is an interesting element of longevity. As baby boomers age, they’re expected to transfer their wealth to Gen X, millennials and Gen Z to the tune of tens or even hundreds of trillions of U.S. dollars.
Estimates vary widely, but the amounts are unprecedented. And so, inheritance isn’t just a family milestone. It’s becoming an important cornerstone of financial planning and longevity. And understanding who’s receiving, expecting, and using their inheritances is key to forecasting how Americans save, spend, and invest.
According to our latest, AlphaWise survey, 17 percent of U.S. consumers have received an inheritance, and another 14 percent expect to receive one in the future. Younger Americans are especially optimistic. Their expectations split evenly between those anticipating an inheritance within the next 10 years and those expecting it further out.
But here’s the kicker; income plays a huge role. Only 17 percent of lower income consumers report receiving or expecting an inheritance, but that number jumps to 43 percent among higher income households highlighting a clear wealth divide.
What about the size of the inheritance? In our survey, those who received or expect to receive an inheritance fall broadly into three categories. About half reported amounts under $100,000 dollars. For about a third, that amount rose to under $500,000. And then meanwhile, 10 per cent reported an inheritance of half a million dollars or more.
Younger consumers tend to report smaller amounts, while inheritance size rises with income. One important thing to remember about our survey though, is it looks more at the average person. We are missing some of those very high net worth demographics in there where I would expect inheritance to rise much higher than half a million.
And so, when we think about this, how will recipients use this wealth? That’s a really important question. The majority, about 60 percent, say they have or will put their inheritance towards savings, retirement, or investments. About a third say they’ll use it for housing or paying down debt. Day-to-day consumption, travel, education and even starting a business or giving to charity also featured in the survey responses – but to a lesser extent.
The financial impact of inheritance is significant: 46 percent of recipients say it makes them feel more financially secure; 40 percent cite improvements in savings and; 22 percent associate it with increased spending. Some even report retiring earlier or lightening their workloads.
Inheritance trends are shaping consumer behavior and have the power to influence spending patterns across industries. To sum it up, inheritance isn’t just a family matter, it’s a market mover.
Thanks for listening. If you enjoy the show, please leave us a review wherever you listen, and share Thoughts on the Market with a friend or colleague today.
Michigan State University scientists have pinpointed the molecular “switch” that supercharges sperm for their final sprint to an egg — a breakthrough that could reshape infertility treatments and pave the way for safe, nonhormonal male…
Findings presented at the International VT Symposium and published simultaneously in Circulation.
CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/ — Field Medical, Inc. today announced that
New Brunswick, New Jersey (October 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota’s offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 2025, the last full trading day prior to the date of the offer. Moreover, the offer is conditioned on, among other things, the closing price per share of Johnson & Johnson common stock exceeding $145.00 on the last trading day before the offer expires. This means that unless this condition is waived by Tutanota, Johnson & Johnson shareholders who tender their shares in the offer will receive a below-market price. Tutanota further states in its offering documents that it expects to extend the offer for successive periods of 45 to 180 days until the market price of the shares exceeds the offer price. The offer is for approximately 0.0207% of the shares of Johnson & Johnson common stock outstanding as of the September 29, 2025 offer date.
Johnson & Johnson is not associated in any way with Tutanota LLC or its unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to Tutanota’s offer because the offer is at a price below the current market price for Johnson & Johnson’s shares and subject to numerous conditions.
Tutanota has made many similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire less than 5 percent of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (SEC) that would otherwise apply. As a result, mini-tender offers do not provide investors with the same level of protections as provided for larger tender offers under U.S. securities laws.
The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” More on the SEC’s guidance to investors on mini-tender offers is available at
https://www.sec.gov/rules-regulations/2000/07/commission-guidance-mini-tender-offers-limited-partnership-tender-offers.
Johnson & Johnson urges investors to obtain current market quotations for their shares, to consult with their broker or financial advisor and to exercise caution with respect to Tutanota’s offer. Johnson & Johnson recommends that shareholders who have not responded to Tutanota’s offer take no action. The offer is currently scheduled to expire at 5:00 p.m., New York City time, on Wednesday, October 29, 2025, unless extended or earlier terminated.
Johnson & Johnson encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at
www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at
www.jnj.com.
Written by BENJAMIN PERCY
Art and Cover by GEOFF SHAW
On Sale 2/11
DANGEROUS. UNHINGED. DEADLY. Deadpool is a man on the brink, and that means the jobs are deadlier, the stakes are higher, and the humor is darker than ever before. But Wade Wilson…
Replacing F-18 sodium fluoride (NaF) PET/CT imaging with F-18 prostate-specific membrane antigen (PSMA) PET/CT can improve treatment decisions among men with newly diagnosed prostate cancer, researchers in Denmark have reported.
Among 160…
After 15 years, four records and a buzz-making barrage of shows, tours and festivals, the moody, multifaceted music of north London’s Wolf Alice is huge in the U.K., thanks to uniquely seductive soundscapes, visceral live shows and a…
